Market Cap
€41.8b
Last Updated
2020/10/22 21:00 UTC
Data Sources
Company Financials +
Executive Summary
Bayer Aktiengesellschaft operates as a life science company worldwide. More Details
Rewards
Risk Analysis
Snowflake Analysis
Established dividend payer and fair value.
Similar Companies
Share Price & News
How has Bayer's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: BAYN's share price has been volatile over the past 3 months.
Market Performance
7 Day Return
-4.0%
BAYN
-3.0%
DE Pharmaceuticals
-3.2%
DE Market
1 Year Return
-37.1%
BAYN
1.1%
DE Pharmaceuticals
0.2%
DE Market
Return vs Industry: BAYN underperformed the German Pharmaceuticals industry which returned 1.1% over the past year.
Return vs Market: BAYN underperformed the German Market which returned 0.2% over the past year.
Shareholder returns
| BAYN | Industry | Market | |
|---|---|---|---|
| 7 Day | -4.0% | -3.0% | -3.2% |
| 30 Day | -21.4% | -9.2% | 1.0% |
| 90 Day | -30.3% | -11.2% | -2.9% |
| 1 Year | -34.2%-37.1% | 4.4%1.1% | 3.4%0.2% |
| 3 Year | -56.9%-62.4% | 22.2%8.2% | 1.0%-7.8% |
| 5 Year | -57.9%-65.0% | 22.2%1.2% | 21.1%3.8% |
Price Volatility Vs. Market
How volatile is Bayer's share price compared to the market and industry in the last 5 years?
Simply Wall St News
2 months ago | Simply Wall St
A Look At Bayer's (ETR:BAYN) Share Price Returns3 months ago | Simply Wall St
How Much Is Bayer Aktiengesellschaft (ETR:BAYN) CEO Getting Paid?Valuation
Is Bayer undervalued compared to its fair value and its price relative to the market?
>50%
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: BAYN (€42.33) is trading below our estimate of fair value (€118.49)
Significantly Below Fair Value: BAYN is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: BAYN is unprofitable, so we can't compare its PE Ratio to the XE Pharmaceuticals industry average.
PE vs Market: BAYN is unprofitable, so we can't compare its PE Ratio to the German market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate BAYN's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: BAYN is good value based on its PB Ratio (1.2x) compared to the DE Pharmaceuticals industry average (6.2x).
Next Steps
Future Growth
How is Bayer forecast to perform in the next 1 to 3 years based on estimates from 23 analysts?
56.5%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: BAYN is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (0.2%).
Earnings vs Market: BAYN is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: BAYN's is expected to become profitable in the next 3 years.
Revenue vs Market: BAYN's revenue (2.1% per year) is forecast to grow slower than the German market (6.1% per year).
High Growth Revenue: BAYN's revenue (2.1% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: BAYN's Return on Equity is forecast to be low in 3 years time (14.7%).
Next Steps
Past Performance
How has Bayer performed over the past 5 years?
-33.0%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: BAYN is currently unprofitable.
Growing Profit Margin: BAYN is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: BAYN is unprofitable, and losses have increased over the past 5 years at a rate of 33% per year.
Accelerating Growth: Unable to compare BAYN's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: BAYN is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (13.2%).
Return on Equity
High ROE: BAYN has a negative Return on Equity (-20.23%), as it is currently unprofitable.
Next Steps
Financial Health
How is Bayer's financial position?
Financial Position Analysis
Short Term Liabilities: BAYN's short term assets (€32.8B) do not cover its short term liabilities (€36.5B).
Long Term Liabilities: BAYN's short term assets (€32.8B) do not cover its long term liabilities (€51.3B).
Debt to Equity History and Analysis
Debt Level: BAYN's debt to equity ratio (111.1%) is considered high.
Reducing Debt: BAYN's debt to equity ratio has increased from 108.6% to 111.1% over the past 5 years.
Debt Coverage: BAYN's debt is not well covered by operating cash flow (19.4%).
Interest Coverage: BAYN is unprofitable, therefore interest payments are not well covered by earnings.
Balance Sheet
Next Steps
Dividend
What is Bayer current dividend yield, its reliability and sustainability?
6.61%
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: BAYN's dividend (6.61%) is higher than the bottom 25% of dividend payers in the German market (1.22%).
High Dividend: BAYN's dividend (6.61%) is in the top 25% of dividend payers in the German market (3.77%)
Stability and Growth of Payments
Stable Dividend: BAYN's dividends per share have been stable in the past 10 years.
Growing Dividend: BAYN's dividend payments have increased over the past 10 years.
Current Payout to Shareholders
Dividend Coverage: BAYN is paying a dividend but the company is unprofitable.
Future Payout to Shareholders
Future Dividend Coverage: BAYN's dividends in 3 years are forecast to be well covered by earnings (33.8% payout ratio).
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
4.4yrs
Average management tenure
CEO
Werner Baumann (58 yo)
4.42yrs
Tenure
€7,461,000
Compensation
Mr. Werner Baumann has been Chairman of Management Board and Chief Executive Officer at Bayer AG since May 1, 2016 and has been its Member of Management Board since January 1, 2010. Since January 1, 2020, ...
CEO Compensation Analysis
Compensation vs Market: Werner's total compensation ($USD8.83M) is above average for companies of similar size in the German market ($USD5.28M).
Compensation vs Earnings: Werner's compensation has increased whilst the company is unprofitable.
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman of Management Board | 4.42yrs | €7.46m | no data | |
| CFO & Member of Management Board | 2.33yrs | €3.22m | no data | |
| Member of Management Board & President of Bayer Crop Science Division | 4.75yrs | €4.41m | no data | |
| Head of Consumer Health Division & Member of Management Board | 2.58yrs | €3.53m | no data | |
| President of Pharmaceuticals Division & Member of the Board of Management | 1.92yrs | €4.03m | no data | |
| Head of Accounting and Head of Taxes | 4.5yrs | no data | no data | |
| Head of Investor Relations | 3.58yrs | no data | no data | |
| Head of Law | no data | no data | no data | |
| Head of Communications | 4.42yrs | no data | no data | |
| Global Product Director | no data | no data | no data | |
| Head of Mergers | no data | no data | no data | |
| Head of Finance for Corporate Center | 9.17yrs | no data | no data |
4.4yrs
Average Tenure
52yo
Average Age
Experienced Management: BAYN's management team is considered experienced (4.4 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Member of Supervisory Board | 18.5yrs | €204.00k | no data | |
| Member of Supervisory Board | 4.5yrs | €275.00k | no data | |
| Member of Supervisory Board | 6.5yrs | €137.00k | no data | |
| Chairman of Executive Board - Bayer Business Services | no data | no data | no data | |
| Member of Supervisory Board | 8.5yrs | €205.00k | no data | |
| Member of Supervisory Board | 14yrs | €135.00k | no data | |
| Vice Chairman of Supervisory Board | 5.25yrs | €270.00k | no data | |
| Chairman of Executive Board - Currenta | no data | no data | no data | |
| Member of Supervisory Board | 0.50yr | no data | no data | |
| Member of Supervisory Board | 8.5yrs | €205.00k | no data | |
| Member of Supervisory Board | 8.5yrs | €137.00k | no data | |
| Chairman of Supervisory Board | 0.50yr | €290.00k | no data |
7.5yrs
Average Tenure
62.5yo
Average Age
Experienced Board: BAYN's board of directors are considered experienced (7.5 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 5.3%.
Top Shareholders
Company Information
Bayer Aktiengesellschaft's company bio, employee growth, exchange listings and data sources
Key Information
- Name: Bayer Aktiengesellschaft
- Ticker: BAYN
- Exchange: XTRA
- Founded: 1863
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: €41.753b
- Shares outstanding: 982.42m
- Website: https://www.bayer.com
Number of Employees
Location
- Bayer Aktiengesellschaft
- Kaiser-Wilhelm-Allee 1
- Leverkusen
- North Rhine-Westphalia
- 51368
- Germany
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| BAYR.Y | OTCPK (Pink Sheets LLC) | SPON ADR-EACH REPR 1 ORD NPV | US | USD | Dec 1972 | |
| BAYA | DB (Deutsche Boerse AG) | SPON ADR-EACH REPR 1 ORD NPV | DE | EUR | Dec 1972 | |
| BAYA | XTRA (XETRA Trading Platform) | SPON ADR-EACH REPR 1 ORD NPV | DE | EUR | Dec 1972 | |
| BAYZ.F | OTCPK (Pink Sheets LLC) | Yes | Registered Shares | US | USD | Jan 1975 |
| 0P6S | LSE (London Stock Exchange) | Yes | Registered Shares | GB | EUR | Jan 1975 |
| BAYN | DB (Deutsche Boerse AG) | Yes | Registered Shares | DE | EUR | Jan 1975 |
| BAYN | SWX (SIX Swiss Exchange) | Yes | Registered Shares | CH | CHF | Jan 1975 |
| BAY | BIT (Borsa Italiana) | Yes | Registered Shares | IT | EUR | Jan 1975 |
| BAYN | XTRA (XETRA Trading Platform) | Yes | Registered Shares | DE | EUR | Jan 1975 |
| BAYER | BUSE (Budapest Stock Exchange) | Yes | Registered Shares | HU | HUF | Jan 1975 |
| BAYND | BATS-CHIXE (BATS 'Chi-X Europe') | Yes | Registered Shares | GB | EUR | Jan 1975 |
| BAYN N | BMV (Bolsa Mexicana de Valores) | Yes | Registered Shares | MX | MXN | Jan 1975 |
| BAYN | WBAG (Wiener Boerse AG) | Yes | Registered Shares | AT | EUR | Jan 1975 |
| BAY018 | DB (Deutsche Boerse AG) | NPV (NEW) | DE | EUR | Jan 2018 |
Biography
Bayer Aktiengesellschaft operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription produ ...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2020/10/22 21:00 |
| End of Day Share Price | 2020/10/22 00:00 |
| Earnings | 2020/06/30 |
| Annual Earnings | 2019/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.